Leadership

    We’ve assembled an experienced team with substantial genetic medicines, orphan drug development, and technology development expertise from small and large biopharma companies.
    Heather L. Clark, M.S.

    Chief Executive Officer

    Vladimir Kharitonov, Ph.D.

    Chief Technical Officer

    Sakya Mohapatra

    Executive Director, Pharmaceutical Sciences

    Priya Ryali, MBA

    Executive Director, Head of Clinical Operations

    Max Barker, J.D.
    Max Barker, J.D.

    General Counsel

    Shehnaaz Suliman, M.D., M.B.A., M.Phil.

    President & Chief Executive Officer

    John G. Matthews, MBBS, MRCP, Ph.D.

    Chief Medical Officer

    Jessica Couch
    Jessica Couch, Ph.D.

    Chief Scientific Officer

    Vladimir Kharitonov, Ph.D.

    Chief Technology Officer

    Max Barker, J.D.
    Max Barker, J.D.

    General Counsel

    Heather L. Clark, M.S.

    Chief Executive Officer

    Board of Directors

    Shehnaaz Suliman, M.D., M.B.A., M.Phil.

    Executive Chair
    Heather L. Clark, M.S.
    Rana Al-Hallaq, Ph.D.

    Pfizer Ventures
    Alan Colowick, M.D., M.P.H.

    Matrix Capital Management Company
    Ed Hurwitz, J.D., M.B.A.

    MPM Capital

    Scientific Advisory Board

    Daniel J. Siegwart, Ph.D.

    Chair of the SAB
    Andrew Bellinger, M.D., Ph.D.
    Justin Hanes, Ph.D.
    Katalin Karikó, Ph.D.
    David J. Lockhart, Ph.D.
    Eric Olson, Ph.D.
    Elliott Sigal, M.D., Ph.D.

    Scientific Advisor

    Investors